PCF 2019 VL

Aiding Cancer Prevention and Treatment by Renaming the BRCA1, BRCA2, and BRCA3 Mutations - Colin Pritchard

Details
Colin Pritchard from the University of Washington joins Charles Ryan at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) to speak about his recent editorial that was published in Nature that advocates for a renaming of the genetic syndrome that we commonly call BRCA2 mutation or the "breast cancer gene". They're named the breast cancer genes but it is limiting because prost...

Disparities and Outcomes in Men with Prostate Cancer - Susan Halabi, Mindy Hebert-DeRouen, and Daniel George

Details
At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019), Charles Ryan is joined by three physicians to discuss disparities and outcomes in men with prostate cancer. Drs. Susan Halabi, Mindy DeRouen, and Dan George shared highlights from their presentations from the PCF Scientific Retreat. Dr. Hebert-DeRouen shares details on the Disparities Research: Environment and multi oMics...

The Journey of an Aspirational Leader - Lynn Seely

Details
President and CEO of Myovant Sciences, Lynn Seely, MD joins Alicia Morgans, MD and shares highlights of her career journey also presented in her keynote during the 4th Annual PCF Women in Science Forum at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019). Dr. Seely shares elements from her career journey including her internship and residency in internal medicine at Yale, he...

New Therapeutic Targets for Metastatic Castration-Resistant Prostate Cancer - Aaron LeBeau

Details
At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019), Charles Ryan is joined by his colleague Aaron Le Beau from the University of Minnesota who specializes in the developments of targeted imaging agents and therapeutics for prostate cancer using novel antibody constructs. Drs. Ryan and LeBeau discuss the work he is doing on potential alternate targets to PSMA. Antibodies we...

The IRONMAN - An International Registry for Men with Advanced Prostate Cancer - Dana Rathkopf

Details
At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) Dana Rathkopf and Alicia Morgans discuss the IRONMAN registry. Dana, a strong contributor to the IRONMAN registry trial, explains the goals of the registry and why it is so important for the personalization of patient care around the world. The IRONMAN registry is a population-based observational study currently in nine co...

The Current State of Cell-free DNA in Prostate Cancer - Alexander Wyatt

Details
Alexander Wyatt from the University of British Columbia joins Charles Ryan at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) to talk about the current state of cell-free DNA and what a clinician can use in the treatment of prostate cancer from cell-free DNA for current testing. Biographies: Alexander Wyatt, Ph.D., BSc, Assistant Professor, Department of Urologic Sciences,...

Exercise vs. Usual Care Among Men Opting for Active Surveillance for Prostate Cancer - June Chan

Details
At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019), Professor June Chan joins Charles Ryan to discuss her work with patients on active surveillance (AS) for prostate cancer and a current ongoing study of lifestyle modification. Early data suggest that exercise after diagnosis could help with delaying or deterring prostate cancer recurrence or progression. The AS RCT study...

Prolonging Time to Metastatic Disease, The SPARTAN Study - Matthew Smith

Details
In this conversation with Alicia Morgans, Matthew Smith shares highlights from his 2019 European Society for Medical Oncology annual meeting, (ESMO) presentation. He presented the updated survival results from SPARTAN, A study of apalutamide (ARN-509) in men with non-metastatic castration-resistant prostate cancer (nmCRPC), a pivotal study which led to the approval of apalutamide for men with nmCR...

Precision Oncology: The PCF - Veterans Affairs (VA) Initiative - Bruce Montgomery

Details
Bruce Montgomery shares an update on the PCF - VA research Initiative on precision oncology in prostate cancer. Prostate Cancer Foundation has provided a $50 million dollar contribution to this VA specific prostate cancer effort. Bruce and Chuck Ryan discuss the developments to date and the future plans. Biographies: Bruce Montgomery, MD Board-certified oncologist, clinical director of Genitourina...